GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Cardiff Oncology Inc (STU:XE7C) » Definitions » Shiller PE Ratio

Cardiff Oncology (STU:XE7C) Shiller PE Ratio : (As of May. 21, 2024)


View and export this data going back to 2015. Start your Free Trial

What is Cardiff Oncology Shiller PE Ratio?

Shiller PE for Stocks: The True Measure of Stock Valuation


Cardiff Oncology Shiller PE Ratio Historical Data

The historical data trend for Cardiff Oncology's Shiller PE Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Cardiff Oncology Shiller PE Ratio Chart

Cardiff Oncology Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Shiller PE Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Cardiff Oncology Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Shiller PE Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Cardiff Oncology's Shiller PE Ratio

For the Biotechnology subindustry, Cardiff Oncology's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Cardiff Oncology's Shiller PE Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Cardiff Oncology's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where Cardiff Oncology's Shiller PE Ratio falls into.



Cardiff Oncology Shiller PE Ratio Calculation

For Shiller PE Ratio, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller PE Ratio is also called PE10.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.

Cardiff Oncology's E10 for the quarter that ended in Mar. 2024 is calculated as:

For example, Cardiff Oncology's adjusted earnings per share data for the three months ended in Mar. 2024 was:

Adj_EPS=Earnings per Share (Diluted)/CPI of Mar. 2024 (Change)*Current CPI (Mar. 2024)
=-0.202/131.7762*131.7762
=-0.202

Current CPI (Mar. 2024) = 131.7762.

Cardiff Oncology Quarterly Data

Earnings per Share (Diluted) CPI Adj_EPS
201406 -9.009 100.560 -11.806
201409 -15.644 100.428 -20.527
201412 -14.598 99.070 -19.417
201503 -21.954 99.621 -29.040
201506 -26.302 100.684 -34.424
201509 -14.755 100.392 -19.368
201512 -17.185 99.792 -22.693
201603 -23.276 100.470 -30.529
201606 -21.787 101.688 -28.233
201609 -21.812 101.861 -28.218
201612 -23.207 101.863 -30.022
201703 -21.542 102.862 -27.597
201706 -16.661 103.349 -21.244
201709 -7.098 104.136 -8.982
201712 -3.650 104.011 -4.624
201803 -5.053 105.290 -6.324
201806 -4.511 106.317 -5.591
201809 -0.943 106.507 -1.167
201812 -0.958 105.998 -1.191
201903 -0.903 107.251 -1.109
201906 -0.673 108.070 -0.821
201909 -0.627 108.329 -0.763
201912 -0.459 108.420 -0.558
202003 -0.371 108.902 -0.449
202006 -0.453 108.767 -0.549
202009 -0.161 109.815 -0.193
202012 -0.148 109.897 -0.177
202103 -0.118 111.754 -0.139
202106 -0.141 114.631 -0.162
202109 -0.145 115.734 -0.165
202112 -0.204 117.630 -0.229
202203 -0.227 121.301 -0.247
202206 -0.227 125.017 -0.239
202209 -0.202 125.227 -0.213
202212 -0.189 125.222 -0.199
202303 -0.233 127.348 -0.241
202306 -0.231 128.729 -0.236
202309 -0.206 129.860 -0.209
202312 -0.193 129.419 -0.197
202403 -0.202 131.776 -0.202

Add all the adjusted EPS together and divide 10 will get our E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Cardiff Oncology  (STU:XE7C) Shiller PE Ratio Explanation

Compared with the regular PE Ratio, which works poorly for cyclical businesses, the Shiller PE Ratio smoothed out the fluctuations of profit margins during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Shiller PE Ratio should give similar results to regular PE Ratio.

Compared with the PS Ratio, the Shiller PE Ratio makes the comparison between different industries more meaningful.


Be Aware

Shiller PE Ratio assumes that over the long term, businesses and profitability revert to their means. If a company's business model does not work in the future compared with the past, Shiller PE Ratio and PS Ratio will give false valuations.


Cardiff Oncology Shiller PE Ratio Related Terms

Thank you for viewing the detailed overview of Cardiff Oncology's Shiller PE Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Cardiff Oncology (STU:XE7C) Business Description

Traded in Other Exchanges
Address
11055 Flintkote Avenue, San Diego, CA, USA, 92121
Cardiff Oncology Inc is a clinical-stage, biotechnology company, developing treatment options for cancer patients in indications with the greatest medical need, including KRAS-mutated metastatic colorectal cancer, pancreatic cancer, metastatic castrate-resistant prostate cancer and leukemias.

Cardiff Oncology (STU:XE7C) Headlines

No Headlines